JP2020531586A - 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物 - Google Patents

合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物 Download PDF

Info

Publication number
JP2020531586A
JP2020531586A JP2020532845A JP2020532845A JP2020531586A JP 2020531586 A JP2020531586 A JP 2020531586A JP 2020532845 A JP2020532845 A JP 2020532845A JP 2020532845 A JP2020532845 A JP 2020532845A JP 2020531586 A JP2020531586 A JP 2020531586A
Authority
JP
Japan
Prior art keywords
arginine
tranexamic acid
virus
synthetic lysine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020532845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531586A5 (https=
Inventor
フランク マードック，
フランク マードック，
ロンエア マードック，
ロンエア マードック，
ダブリュ． ポール スチュワート，
ダブリュ． ポール スチュワート，
Original Assignee
アンタイ−ヴァイラル テクノロジーズ， エルエルシー
アンタイ−ヴァイラル テクノロジーズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンタイ−ヴァイラル テクノロジーズ， エルエルシー, アンタイ−ヴァイラル テクノロジーズ， エルエルシー filed Critical アンタイ−ヴァイラル テクノロジーズ， エルエルシー
Publication of JP2020531586A publication Critical patent/JP2020531586A/ja
Publication of JP2020531586A5 publication Critical patent/JP2020531586A5/ja
Priority to JP2023088440A priority Critical patent/JP2023123440A/ja
Priority to JP2025129144A priority patent/JP2025166032A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020532845A 2017-08-27 2018-08-09 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物 Withdrawn JP2020531586A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023088440A JP2023123440A (ja) 2017-08-27 2023-05-30 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
JP2025129144A JP2025166032A (ja) 2017-08-27 2025-08-01 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762550656P 2017-08-27 2017-08-27
US62/550,656 2017-08-27
US201862664555P 2018-04-30 2018-04-30
US62/664,555 2018-04-30
PCT/US2018/046023 WO2019045989A1 (en) 2017-08-27 2018-08-09 METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088440A Division JP2023123440A (ja) 2017-08-27 2023-05-30 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2020531586A true JP2020531586A (ja) 2020-11-05
JP2020531586A5 JP2020531586A5 (https=) 2021-09-16

Family

ID=65525881

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020532845A Withdrawn JP2020531586A (ja) 2017-08-27 2018-08-09 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
JP2023088440A Withdrawn JP2023123440A (ja) 2017-08-27 2023-05-30 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
JP2025129144A Pending JP2025166032A (ja) 2017-08-27 2025-08-01 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023088440A Withdrawn JP2023123440A (ja) 2017-08-27 2023-05-30 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
JP2025129144A Pending JP2025166032A (ja) 2017-08-27 2025-08-01 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物

Country Status (11)

Country Link
US (3) US11413279B2 (https=)
EP (2) EP4681713A2 (https=)
JP (3) JP2020531586A (https=)
KR (1) KR102706114B1 (https=)
CN (1) CN111315374A (https=)
AU (2) AU2018324427B2 (https=)
BR (1) BR112020003735A2 (https=)
CA (1) CA3073685A1 (https=)
MX (2) MX2020002156A (https=)
WO (1) WO2019045989A1 (https=)
ZA (1) ZA202001472B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022132181A (ja) * 2021-02-26 2022-09-07 ライオン株式会社 コロナウイルスの細胞侵入抑制剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220127227A (ko) * 2019-10-29 2022-09-19 트라넥사믹 테크놀로지스, 엘엘씨 강화된 효능을 위한 합성 라이신 유사체, 유도체, 모방체 또는 프로드럭, 및 약제의 시너지 조합
WO2021162879A1 (en) * 2020-02-14 2021-08-19 Tranexamic Technologies, Llc Methods and compositions for antimicrobial use of synthetic lysine analogs, derivatives, mimetics, and prodrugs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509589A (ja) * 1994-10-28 1998-09-22 クロディカ エス．アー． プロテアーゼ阻害剤および他の生物活性物質の新しい系
WO2004032915A1 (ja) * 2002-10-11 2004-04-22 Daiichi Pharmaceutical Co., Ltd. 抗インフルエンザウイルス剤
JP2008115168A (ja) * 2006-10-12 2008-05-22 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤
JP2012509081A (ja) * 2008-11-20 2012-04-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド ウイルスのアルギニン不活化

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037071A1 (en) * 1998-12-21 2000-06-29 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
ES2156731B1 (es) * 1999-05-31 2002-02-16 Grifols Grupo Sa Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
US7056947B2 (en) 2002-07-05 2006-06-06 Georgia Tech Research Corp. Aza-peptide epoxides
JP2010189301A (ja) * 2009-02-17 2010-09-02 Toshihito Eto 新型インフルエンザ感染症に対する医薬組成物およびその利用
US20120082677A1 (en) * 2010-10-01 2012-04-05 Sherif Salah Abdul Aziz Compositions for the treatment of hcv and hbv
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
CN103405384B (zh) * 2013-09-01 2015-05-13 吴静 氨甲环酸的药物组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509589A (ja) * 1994-10-28 1998-09-22 クロディカ エス．アー． プロテアーゼ阻害剤および他の生物活性物質の新しい系
WO2004032915A1 (ja) * 2002-10-11 2004-04-22 Daiichi Pharmaceutical Co., Ltd. 抗インフルエンザウイルス剤
JP2008115168A (ja) * 2006-10-12 2008-05-22 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤
JP2012509081A (ja) * 2008-11-20 2012-04-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド ウイルスのアルギニン不活化

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, JPN6023001472, 2014, pages 538 - 543, ISSN: 0004977583 *
FRONTIERS IN AGING NEUROSCIENCE, vol. 6, JPN6022017018, 2014, pages 285, ISSN: 0004768489 *
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 23, JPN6022017021, 2009, pages 495 - 499, ISSN: 0004977582 *
JOURNAL OF CLINICAL MICROBIOLOGY, vol. 42, JPN6022017025, 2004, pages 5861 - 5865, ISSN: 0004977580 *
JOURNAL OF NEUROVIROLOGY, vol. 14, JPN6022017019, 2008, pages 1 - 4, ISSN: 0004768488 *
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 127, no. 7, JPN6023001473, July 2017 (2017-07-01), pages 2626 - 2630, ISSN: 0004977584 *
THROMBOSIS AND HAEMOSTASIS, vol. 107, JPN6022017023, 2012, pages 760 - 768, ISSN: 0004977581 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022132181A (ja) * 2021-02-26 2022-09-07 ライオン株式会社 コロナウイルスの細胞侵入抑制剤
JP7830159B2 (ja) 2021-02-26 2026-03-16 ライオン株式会社 コロナウイルスの細胞侵入抑制剤

Also Published As

Publication number Publication date
EP3672584A1 (en) 2020-07-01
US20220288050A1 (en) 2022-09-15
KR102706114B1 (ko) 2024-09-11
WO2019045989A1 (en) 2019-03-07
MX2020002156A (es) 2020-07-20
CN111315374A (zh) 2020-06-19
AU2018324427B2 (en) 2024-03-07
AU2018324427A1 (en) 2020-04-09
JP2023123440A (ja) 2023-09-05
AU2024203839A1 (en) 2024-06-27
MX2023009499A (es) 2023-08-23
CA3073685A1 (en) 2019-03-07
JP2025166032A (ja) 2025-11-05
US20200323837A1 (en) 2020-10-15
BR112020003735A2 (pt) 2020-09-01
EP4681713A2 (en) 2026-01-21
ZA202001472B (en) 2022-05-25
EP3672584A4 (en) 2021-05-05
KR20200052310A (ko) 2020-05-14
US11413279B2 (en) 2022-08-16
US20260007649A1 (en) 2026-01-08

Similar Documents

Publication Publication Date Title
JP2025166032A (ja) 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
AU2002311890B2 (en) Method for treatment of tumors using nordihydroguaiaretic acid derivatives
CN102458476A (zh) 用于治疗多发性硬化症的组合物及方法
US9682130B2 (en) Viral conjunctivitis treatment using Ranpirnase and/or Amphinase
CN1838885A (zh) 治疗皮肤的疮和损害的方法
JPH06507386A (ja) 治療用ペプチド
US10413586B2 (en) Antiviral agent comprising recombinant mistletoe lectins
NZ536360A (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
DK2374461T3 (en) Piroxicam for the prophylactic and therapeutic treatment of herpes infections
CN1213757C (zh) Dna病毒感染的协同治疗
HK40026056A (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
Kamangar et al. CUTIS Do Not Copy
CN114929212A (zh) 用于增强功效的合成的赖氨酸类似物、衍生物、模拟物或前药与药剂的协同组合
US9757396B2 (en) Method for treating recurring skin and mucous membrane diseases caused by HSV-1 and HSV-2
WO2012070967A1 (ru) Ранозаживляющая, противоожоговая, регенерирующая и противовирусная фармацевтическая композиция для местного применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230704

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230711